title: Mesalazine-induced lung fibrosis.
abstract: The medical management of a patient with Crohn's disease should take into account the activity, site and behaviour of disease, and should be discussed with the patient, and 5-aminosalicylates are a group of medications which have been commonly used. Sulfasalazine is a combination of 5-aminosalicylic acid and sulfapyridine which acts only as a carrier to the colonic site of action but can still cause systemic side-effects including lung disease. In mesalazine the specific sulfapyridine-related side-effects, especially pulmonary reactions, are avoided. However, we present a case of lung fibrosis which was associated with mesalazine in a Crohn's patient.
authors.affiliation: Departments of Respiratory Medicine and Gastroenterology, Northern General Hospital, Sheffield, UK. e.alskaf@nhs.net
authors.forename: Ebraheem
authors.initials: E
authors.lastname: Alskaf
authors.forename: Amer
authors.initials: A
authors.lastname: Aljoudeh
authors.forename: Frank
authors.initials: F
authors.lastname: Edenborough
mesh_terms: D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000009:adverse effects*; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine